Napththalene derivatives which inhibit the cytokine or biological activity of macrophage migration inhibitory factor (MIF)

A biological activity, cytokine technology, applied in the direction of sugar derivatives, sugar derivatives, organic active ingredients, etc.

Inactive Publication Date: 2005-09-28
CORTICAL PTY LTD
View PDF1 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Supporting this hypothesis was the finding that anti-MIF antibody therapy reversed the effects of adrenalectomy in adjuvant arthritis in rats (9)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Napththalene derivatives which inhibit the cytokine or biological activity of macrophage migration inhibitory factor (MIF)
  • Napththalene derivatives which inhibit the cytokine or biological activity of macrophage migration inhibitory factor (MIF)
  • Napththalene derivatives which inhibit the cytokine or biological activity of macrophage migration inhibitory factor (MIF)

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0434] Example 1: 6,7-dimethoxy-2-naphthalene

[0435] 2,3-Dimethoxynaphthalene

[0436]

[0437] (1) (2)

[0438] A suspension of 2,3-dihydroxynaphthalene (5.00 g, 0.0312 mol) in water (25 mL) in a three-neck round bottom flask was cooled with an ice bath. Two constant pressure funnels were installed and dimethyl sulfate (7.20 mL, 9.57 g, 0.0759 mol) and aqueous potassium hydroxide (5.57 g, 0.0993 mol, 17.0 mL of water) were charged into the two funnels respectively. The two solutions were added dropwise together over 10 minutes, initially the suspension dissolved and then a precipitate formed. The reaction was left overnight at room temperature. The solid was filtered, washed with water until the washing liquid was neutral (5×200 mL), and then dried to obtain 2,3-dimethoxynaphthalene (4.09 g, yield 70%) as a white powder;

[0439] R f : 0.71 (19:1 CHCl 3 : MeOH), 0.82 (9:1 CHCl 3 : MeOH),

[0440] mp: 112-113°C, literature mp: 113-116°C;

[0441] ...

Embodiment 2

[0443] Example 2: 6,7-dimethoxy-2-acetylnaphthalene

[0444]

[0445] (twenty three)

[0446] A suspension of aluminum chloride (6.02 g, 0.0451 mol) in sieve-dried nitrobenzene (10 mL) was cooled in an ice bath, and acetyl chloride (3.57 mL, 3.93 g, 0.0501mol). A solution of 2,3-dimethoxynaphthalene (7.52 g, 0.0400 mol) in nitrobenzene (25 mL) was added over 10 minutes. The reaction was stirred at 0°C for an additional 60 minutes and then left at room temperature overnight. The mixture was poured into a mixture of ice (60 g) and 10% HCl (100 mL). Chloroform (300 mL) was added and the two phases were separated. The aqueous layer was further extracted with chloroform (2 x 150 mL), the combined organic layers were washed with 5% aqueous sodium hydroxide (3 x 100 mL) and water (2 x 100 mL), dried over anhydrous sodium sulfate, filtered and evaporated in vacuo to give a brown Oil. The oil was purified by flash column chromatography (silica gel, chloroform) ...

Embodiment 3

[0451] Example 3: 6,7-dimethoxy-2-naphthoic acid

[0452]

[0453] (3) (4)

[0454] Sodium hypochlorite (55 mL, 12.5% ​​w / v) was first added to a solution of sodium hydroxide (1.80 g, 0.0450 mole) in water (5.5 mL). The solution was heated gently to 45°C, then 6,7-dimethoxy-2-acetylnaphthalene (2.50 g. 0.0187 mole) was added. When the temperature was gradually raised to 85°C, the suspension dissolved, and the solution was kept at 85°C for another 60 minutes. The solution was then cooled to room temperature and filtered to remove a small amount of orange gum. Then add a small amount of sodium bisulfite (the amount at the end of the spatula) to the filtrate until the iodine / starch paper no longer turns black. The solution was then cooled in an ice bath, and concentrated hydrochloric acid was added dropwise to pH 1. The resulting white precipitate was filtered off, washed with cold water (3×20 mL), and dried over a desiccant under vacuum to give 6,7-dim...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Where Y, R1-R8 and R101-R108 are as defined in the specification. Compounds of formula (II) and methods of inhibiting the cytokine or biological activity of Macrophage Migrating Inhibitory Factor (MIF) comprising contacting MIF with a compound of formula (I) are provided. The invention also relates to methods of treating diseases or conditions where MIF cytokine or biological activity is implicated comprising administration of compounds of formula (I), either alone or as part of a combination therapy.

Description

field of invention [0001] The present invention generally relates to methods of treatment of diseases or conditions caused by cellular activation, such as inflammatory or cancerous diseases or conditions. In particular, the present invention relates to the use of naphthalene derivatives for inhibiting the cytokine or biological activity of macrophage migration inhibitory factor (MIF) and diseases or conditions related to the cytokine or biological activity of MIF. Background of the invention [0002] MIF was the first identified T-cell derived soluble lymphokine. MIF was initially described as a soluble factor with the ability to modify macrophage motility (1). In 1989, molecules responsive to biological actions attributed to MIF were identified and cloned (2). Originally found to activate macrophages at sites of inflammation, it has been shown to have a pluripotent role in the immune system. MIF has been shown to be expressed in human diseases including inflammation, inj...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/075A61K31/12A61K31/185A61K31/192A61K31/205A61K31/216A61K31/255A61K31/277A61K31/357A61K31/4184A61K31/585A61P25/00A61P29/00A61P31/00A61P35/00A61P37/00A61P43/00C07C43/205C07C43/225C07C43/23C07C45/00C07C45/46C07C49/84C07C57/50C07C59/58C07C65/24C07C65/28C07C69/76C07C69/94C07C205/59C07C211/57C07C215/50C07C219/22C07C229/70C07C255/37C07C309/47C07C309/60C07C309/75C07C323/43C07C333/04C07D235/26C07D307/83C07D319/18C07D319/22C07D403/12C07H13/10
CPCC07D235/26C07C69/94C07C43/225C07C309/60C07H13/10C07C43/23C07C45/46C07C45/004C07C309/75A61K31/585C07C65/28C07C255/37C07C65/24C07C205/59C07C229/70C07D307/83C07D403/12C07C59/58C07D319/18C07C333/04A61K31/4184A61P1/04A61P1/16A61P11/00A61P11/02A61P13/12A61P15/00A61P15/10A61P17/00A61P17/02A61P17/06A61P19/02A61P19/04A61P19/08A61P25/00A61P25/04A61P25/28A61P27/02A61P27/12A61P29/00A61P3/10A61P31/00A61P31/04A61P33/06A61P35/00A61P35/02A61P37/00A61P37/02A61P37/06A61P37/08A61P43/00A61P5/44A61P9/10Y02A50/30C07C47/575C07C49/84
Inventor E·F·莫兰德M·N·伊斯坎德B·丹勒
Owner CORTICAL PTY LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products